explore -WSS

explore

author：explore 2025-10-02 00:52:16 - browse：13

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Startup Neumora takes a novel depression drug to Phase 3

WSS

Zyn nicotine pouches become unlikely player in latest culture war

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

White House pharmacy plagued with problems, investigation finds

FTC sues over Novant Health acquisition of two N.C. hospitals

Google and Epic fight stronger regulation of AI in health care

Philips to halt sales of sleep apnea machines in U.S.

explore

explore

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Venture capital firm's plans to take over Akron hospital face hurdles

Supreme Court strikes down use of affirmative action

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Affirmative action in medical school literally saved lives

Doctors find melanoma drugs effective against rare brain cancer

23andMe had bad news about my health. I wish a person had delivered it

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Affirmative action in medical school literally saved lives

Reconstructing family trees of blood cells may help predict disease

focus

How Medicaid coverage policies for immigrants impact new moms

Biogen walks away from Aduhelm, years after polarizing approval

Humana’s losses in Medicare Advantage tank its stock

Merck CEO won’t testify in Senate, citing no expertise in drug prices

At Orexo, a ‘turning point’ for everything but digital health

Venture capital firm's plans to take over Akron hospital face hurdles

explore

focus

leisure time

knowledge